Knowledge Sourcing Intelligence announces the publication of a new report titled “Aptamers Market - Forecasts from 2020-2025”.
According to the report, The Global Aptamers Market will grow at a CAGR of 23.73% to reach a total market size of US$3834.847 million by 2025, from US$1068.804 million in 2019. The aptamers market is expected to witness a high demand due to its diverse applications across various domains. Aptamers are used in the diagnosis of various diseases, and in the detection of small molecules. Furthermore, they are also employed in pharmaceutical lead selection reagents and functional proteomic levels. The high growth of this market is supported by the fact that they are more effective and efficient as compared to the traditional antibodies, and that too at a lower cost. Rapid advancements in technology are expected to bring a positive impact on the development and utilization of aptamers. Additionally, aptamers are quite flexible in shape due to their ability to form loops and helices. However, lack of skilled professionals that can work with them is expected to restrain the growth of this market, nevertheless, rising literacy and technical know-how will support the transmission of such knowledge throughout the forecast period.
Due to rising disposable incomes in conjunction with technological advancements, the adoption of better medical facilities is expected to grow. Geographically, the North American region is projected to witness high growth in this market due to the rising cases of diseases in this region.The Asia-Pacific region is also projected to face an upsurge in the demand for aptamers owing to the rising awareness of improvements in the health and wellness sectors.
Some of the key developments of the market are:
• In October 2019, a research group of the School of Chinese Medicine (Hong Kong Baptist University) developed a novel aptamer- a single-stranded piece of DNA for the treatment of osteogenesis imperfect (OI) with the aid of Artificial Intelligence (AI). The drug was granted FDA orphan drug designation.
• In May 2019, Aptamer Therapeutics Limited, a part of Aptamer Group announced the collaboration with Dan Wiseman and the Oglesby Leukaemia Research Programme at the University of Manchester and Cancer Research UK to explore the capability of aptamers as therapeutic agents.
With regards to the end-users of the aptamers market, the pharmaceutical companies segment is expected to hold a substantial share of the market and is also expected to increase throughout the forecast period. For the segment by type, DNA based Aptamersare anticipated facing high demand. As far as applications are concerned, the therapeutic segment is anticipated to hold a significant share in this market.
Some of the major players covered as part of the report are Aptagen, LLC,Veraptus, AMS Biotechnology (Europe) Limited, Aptamer Group, Novaptech, and ElixirPharmaamong others.
Segmentation
• By Type
o DNA based Aptamers
o RNA based Aptamers
o Peptide-based Aptamers
• By Application
o Therapeutics
o Diagnostics
o Others
• By End-Users
o Pharmaceutical Companies
o Biotechnological Companies
o Research Institutes
• By Geography
o North America
USA
Canada
Mexico
o South America
Brazil
Argentina
Others
o Europe
United Kingdom
Germany
France
Spain
Others
o The Middle East and Africa
Saudi Arabia
Israel
South Africa
Others
o Asia Pacific
China
India
Australia
Japan
Others
View a sample of the report or purchase a complete study at https://www.knowledge-sourcing.com/report/global-aptamers-market
Knowledge Sourcing Intelligence (KSI) is a market research and consulting organization based out of India. KSI publishes research studies spanning across ten industry verticals. KSI has a team of experienced and young professionals with a singular focus on delivering high-quality research services to enterprises, non-government organizations, government agencies, and research institutes and organizations. We publish hundreds of reports per year centering on a niche and latest technologies.
Knowledge Sourcing Intelligence
539 W. Commerce St #2401
Dallas, TX 75208
Email:
[email protected]
Phone: +1-850-250-1698